Pancreatic Cancer Research

ResearcherUniversity of AlabamaActive in the last 2 years

Donald J Buchsbaum

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2797-5847; OpenAlex author ID A5013488451; NIH RePORTER profile ID 1878952. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 5)
Trials
0
Grants
3
Labs led
1
Collaborators
63
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: none · 2014: 1 paper, 1 grant · 2015: 2 papers, 1 grant · 2016: 4 papers · 2017: 1 paper · 2018: 3 papers · 2019: none · 2020: 1 paper · 2021: 1 paper, 1 grant · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 19

  1. ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.02.11.705411↗
  2. ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12943-025-02288-9↗
  3. ST6GAL1 sialyltransferase promotes acinar to ductal metaplasia and pancreatic cancer progression. Co-author DOI 10.1172/jci.insight.161563↗
  4. Glycosyltransferase ST6Gal-I promotes the epithelial to mesenchymal transition in pancreatic cancer cells. Co-author DOI 10.1074/jbc.ra120.014126↗
  5. PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. Co-author DOI 10.1016/j.tranon.2020.100776↗
  6. 212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. Last author DOI 10.1016/j.nucmedbio.2017.12.004↗
  7. Corrigendum to '212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models' [Nucl Med Biol 58 (2018) 67-73]. Last author DOI 10.1016/j.nucmedbio.2018.03.004↗
  8. ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage. Co-author DOI 10.1074/jbc.m117.808584↗
  9. Retraction of "Design and Synthesis of Novel Cyclic Amine Benzimidazoles for the Treatment of Pancreatic Cancer". Co-author DOI 10.1021/acs.jmedchem.6b01417↗
  10. Surveying the serologic proteome in a tissue-specific kras(G12D) knockin mouse model of pancreatic cancer. Co-author DOI 10.1002/pmic.201500133↗
  11. A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of TRA-8/DR5 Oligomers Predicts TRA-8 Therapeutic Efficacy in Breast and Pancreatic C… First author DOI 10.1007/s11307-015-0913-x↗
  12. RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4. Co-author DOI 10.1016/j.molonc.2016.05.004↗
  13. SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. Last author DOI 10.1158/1535-7163.mct-15-0764↗
  14. S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase. Co-author DOI 10.1038/srep08453↗
  15. Dynamic contrast enhanced magnetic resonance imaging of an orthotopic pancreatic cancer mouse model. Last author DOI 10.3791/52641↗
  16. Will detection of microRNA biomarkers in blood improve the diagnosis and survival of patients with pancreatic cancer? Co-author DOI 10.1001/jama.2013.284665↗
  17. A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model. Co-author DOI 10.1097/mpa.0b013e31823b5f2e↗
  18. A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally… Co-author DOI 10.1007/s00280-010-1383-0↗
  19. Molecular targeted approaches for treatment of pancreatic cancer. Last author DOI 10.2174/138161211796957427↗

Grants 3

  1. Structural Biology Shared Facility P30CA013148↗
  2. Therapy of pancreatic cancer with 212Pb-labeled B7-H3 specific Ab and LDE225 R21CA173120↗
  3. Biostatistics Core P50CA101955↗

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yulia Y. Maxuitenko · 2 shared papers, 2025–2026 · strength 0.41
  2. Adam B. Keeton · 2 shared papers, 2025–2026 · strength 0.41
  3. Sujith Sarvesh · 2 shared papers, 2025–2026 · strength 0.41
  4. Dhana Sekhar Reddy Bandi · 2 shared papers, 2025–2026 · strength 0.41
  5. Ganji Purnachandra Nagaraju · 2 shared papers, 2025–2026 · strength 0.41
  6. Jeremy B. Foote · 2 shared papers, 2025–2026 · strength 0.41
  7. Mehmet Akce · 2 shared papers, 2025–2026 · strength 0.41
  8. Gary Anthony Piazza · 2 shared papers, 2025–2026 · strength 0.41
  9. Asfar Sohail Azmi · 2 shared papers, 2025–2026 · strength 0.41
  10. Bassel F. El‐Rayes · 2 shared papers, 2025–2026 · strength 0.41
  11. Soldano Ferrone · 2 shared papers, 1 shared grant, 2015–2018 · strength 0.38
  12. Edward E. Partridge · 1 shared grant, 2021 · strength 0.38
  13. Lawrence J Delucas · 1 shared grant, 2021 · strength 0.38
  14. William J. Placzek · 1 shared grant, 2021 · strength 0.38
  15. Asmi Chakraborty · 3 shared papers, 2018–2023 · strength 0.36
  16. Susan L Bellis · 3 shared papers, 2018–2023 · strength 0.36
  17. Kurt R. Zinn · 4 shared papers, 2016–2018 · strength 0.33
  18. Christopher Klug · 2 shared papers, 1 shared grant, 2014–2023 · strength 0.30
  19. Upender Manne · 2 shared papers, 2020–2025 · strength 0.29
  20. Colleen M. Britain · 2 shared papers, 2021–2023 · strength 0.27
  21. Austin D. Silva · 2 shared papers, 2021–2023 · strength 0.27
  22. Nikita Bhalerao · 2 shared papers, 2021–2023 · strength 0.27
  23. Selwyn Maurice Vickers · 3 shared papers, 1 shared grant, 2011–2016 · strength 0.21
  24. Julienne L. Carstens · 1 shared paper, 2025 · strength 0.19
  25. Karina Jin Yoon · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.